☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Us FDA
Rigel’s R289 Secures the US FDA’s Fast Track Designation for Treating Lower-Risk Myelodysplastic Syndrome
December 3, 2024
Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy
November 7, 2024
ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)
November 7, 2024
Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dog...
November 7, 2024
Insights+: The US FDA New Drug Approvals in July 2024
August 13, 2024
Insights+: The US FDA New Drug Approvals in June 2024
July 16, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.